Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind study of Brazikumab in moderately to severely active Crohn's disease
2018-004346-42Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brazikumab in Crohn's disease (3 arms), sponsored by AstraZeneca. Primary endpoints: Endoscopic response at Week 12 (Stage 1) and Clinical remission at Week 12 (Stage 1). Status: unknown.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-004346-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004346-42.